Trevi Therapeutics (TRVI) Amortization - Deferred Charges (2018 - 2023)
Trevi Therapeutics' quarterly Amortization - Deferred Charges came in at $7000.0 in Q2 2023, down 82.05% year-on-year from $39000.0 in Q2 2022, and down 68.18% quarter-over-quarter from $22000.0 in Q1 2023.
Trevi Therapeutics has reported Amortization - Deferred Charges for 5 years, with the latest figure at $7000.0 in Q2 2023.
- For the quarter ending Q2 2023, Amortization - Deferred Charges fell 82.05% year-over-year to $7000.0; the trailing twelve-month figure through Dec 2023 stood at $29000.0 (down 78.68% YoY), and the FY2023 full-year result was $30000.0, down 78.1% from the prior year.
- Amortization - Deferred Charges for Q2 2023 stood at $7000.0, down from $22000.0 in the prior quarter.
- The five-year high for Amortization - Deferred Charges was $39000.0 in Q2 2022, with the low at $4000.0 in Q3 2020.
- Average Amortization - Deferred Charges over 4 years is $27666.7, with a median of $30000.0 recorded in 2021.
- Year-over-year, Amortization - Deferred Charges surged 725.0% in 2021 and sank 82.05% in 2023.
- Tracing TRVI's Amortization - Deferred Charges over 4 years: stood at $38000.0 in 2020, then changed by 0.0% to $38000.0 in 2021, then fell by 28.95% to $27000.0 in 2022, then tumbled by 74.07% to $7000.0 in 2023.
- The last three Amortization - Deferred Charges figures came in at $7000.0 (Q2 2023), $22000.0 (Q1 2023), and $27000.0 (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 7,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 22,000.00 |
| Mar 31, 2023 | 22,000.00 |
| Dec 31, 2022 | 27,000.00 |
| Dec 31, 2022 | 27,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 39,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Dec 31, 2021 | 38,000.00 |
| Dec 31, 2021 | 38,000.00 |
| Sep 30, 2021 | 33,000.00 |
| Sep 30, 2021 | 33,000.00 |
| Jun 30, 2021 | 27,000.00 |
| Jun 30, 2021 | 27,000.00 |
| Mar 31, 2021 | 27,000.00 |
| Mar 31, 2021 | 27,000.00 |
| Dec 31, 2020 | 38,000.00 |
| Dec 31, 2020 | 38,000.00 |
| Sep 30, 2020 | 4,000.00 |
| Sep 30, 2020 | 4,000.00 |
| Jun 30, 2018 | 5,000.00 |
| Jun 30, 2018 | 5,000.00 |